Early-Stage Loss of GALNT6 Predicts Poor Clinical Outcome in Colorectal Cancer

The loss of the GALNT6 enzyme in early-stage colorectal cancer predicts poor clinical outcomes. In a study of 679 colorectal tumors, including 574 early-stage and 105 late-stage cancers, loss of GALNT6 expression was a prognostic indicator of reduced overall survival.

Read this Next
About UsOur ProductsCustom SolutionsHow it’s SoldOur ResultsDeliveryContact UsBlogPrivacy PolicyFAQ